Market Closed -
Nasdaq
04:00:00 2024-07-08 pm EDT
|
5-day change
|
1st Jan Change
|
5.64
USD
|
+3.49%
|
|
-5.84%
|
-62.12%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,435
|
870.3
|
459.3
|
741.8
|
293.8
|
-
|
-
|
Enterprise Value (EV)
1 |
3,000
|
506.7
|
419.9
|
729
|
294.8
|
307.7
|
251
|
P/E ratio
|
-31.2
x
|
-10.4
x
|
-3.72
x
|
-3.98
x
|
-1.94
x
|
-1.96
x
|
-2.02
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,906
x
|
-
|
-
|
-
|
-
|
-
|
27
x
|
EV / Revenue
|
2,538
x
|
-
|
-
|
-
|
-
|
-
|
23.1
x
|
EV / EBITDA
|
-69
x
|
-6.07
x
|
-3.3
x
|
-4.3
x
|
-1.77
x
|
-1.74
x
|
-1.52
x
|
EV / FCF
|
-78.3
x
|
-7.37
x
|
-4.63
x
|
-
|
-3.31
x
|
-2.35
x
|
-1.19
x
|
FCF Yield
|
-1.28%
|
-13.6%
|
-21.6%
|
-
|
-30.2%
|
-42.6%
|
-84.1%
|
Price to Book
|
7.99
x
|
2.4
x
|
1.74
x
|
3.92
x
|
9.14
x
|
-26.9
x
|
7.43
x
|
Nbr of stocks (in thousands)
|
39,845
|
40,500
|
40,755
|
49,819
|
52,100
|
-
|
-
|
Reference price
2 |
86.20
|
21.49
|
11.27
|
14.89
|
5.640
|
5.640
|
5.640
|
Announcement Date
|
3/18/21
|
2/28/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.796
|
1.182
|
-
|
-
|
-
|
-
|
-
|
10.87
|
EBITDA
1 |
-
|
-43.46
|
-83.5
|
-127.1
|
-169.4
|
-166.8
|
-176.8
|
-165.6
|
EBIT
1 |
-
|
-43.66
|
-83.56
|
-127.4
|
-170.3
|
-161
|
-168.6
|
-187.4
|
Operating Margin
|
-
|
-3,693.99%
|
-
|
-
|
-
|
-
|
-
|
-1,723.66%
|
Earnings before Tax (EBT)
1 |
-
|
-45.5
|
-83.48
|
-123.4
|
-160.8
|
-153.8
|
-150.6
|
-168.8
|
Net income
1 |
-
|
-45.74
|
-83.46
|
-123.5
|
-160.8
|
-157.6
|
-166.5
|
-191.3
|
Net margin
|
-
|
-3,869.71%
|
-
|
-
|
-
|
-
|
-
|
-1,760.11%
|
EPS
2 |
-1.150
|
-2.760
|
-2.070
|
-3.030
|
-3.740
|
-2.908
|
-2.883
|
-2.798
|
Free Cash Flow
1 |
-
|
-38.32
|
-68.77
|
-90.65
|
-
|
-89
|
-131
|
-211
|
FCF margin
|
-
|
-3,241.96%
|
-
|
-
|
-
|
-
|
-
|
-1,940.87%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/5/20
|
3/18/21
|
2/28/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-33.7
|
-36.59
|
-32.11
|
-
|
-
|
-
|
-
|
-
|
-39.6
|
-48.24
|
-42.98
|
-
|
-
|
EBIT
1 |
-28.47
|
-24.75
|
-33.79
|
-36.68
|
-32.22
|
-32.2
|
-36.78
|
-53.28
|
-48.02
|
-37.76
|
-39.45
|
-41.94
|
-42.16
|
-44.08
|
-45.37
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-28.46
|
-24.53
|
-32.92
|
-35.32
|
-30.64
|
-30.18
|
-34.16
|
-50.99
|
-45.47
|
-35.58
|
-38.5
|
-39.33
|
-40.47
|
-40.53
|
-41.96
|
Net income
1 |
-28.44
|
-24.53
|
-32.92
|
-35.32
|
-30.71
|
-30.18
|
-34.16
|
-50.99
|
-45.47
|
-35.58
|
-39.2
|
-40.46
|
-41.98
|
-47.02
|
-48.97
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7000
|
-0.6000
|
-0.8100
|
-0.8700
|
-0.7500
|
-0.7400
|
-0.8400
|
-1.240
|
-0.9300
|
-0.7100
|
-0.7553
|
-0.7347
|
-0.7212
|
-0.7525
|
-0.7200
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/8/22
|
11/8/22
|
3/9/23
|
5/11/23
|
8/10/23
|
11/13/23
|
3/7/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
0.95
|
13.9
|
-
|
Net Cash position
1 |
-
|
434
|
364
|
39.4
|
12.8
|
-
|
-
|
42.9
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.005708
x
|
-0.0786
x
|
-
|
Free Cash Flow
1 |
-
|
-38.3
|
-68.8
|
-90.7
|
-
|
-89
|
-131
|
-211
|
ROE (net income / shareholders' equity)
|
-
|
-25.5%
|
-21.1%
|
-39.4%
|
-71%
|
-144%
|
-1,804%
|
-832%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
10.80
|
8.940
|
6.470
|
3.800
|
0.6200
|
-0.2100
|
0.7600
|
Cash Flow per Share
|
-
|
-2.070
|
-1.690
|
-2.190
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.03
|
0.67
|
1.43
|
1.27
|
0.55
|
1.2
|
1.09
|
Capex / Sales
|
-
|
2.62%
|
-
|
-
|
-
|
-
|
-
|
10.07%
|
Announcement Date
|
5/5/20
|
3/18/21
|
2/28/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
5.64
USD Average target price
21
USD Spread / Average Target +272.34% Consensus |
1st Jan change
|
Capi.
|
---|
| -62.12% | 294M | | +18.43% | 124B | | +19.81% | 114B | | -23.74% | 19.42B | | -18.45% | 16.2B | | -19.97% | 15.31B | | -49.33% | 14.19B | | +57.08% | 14.32B | | +7.95% | 14.31B | | +126.04% | 11.29B |
Bio Therapeutic Drugs
|